Stock Analysis

Fima Corporation Berhad Second Quarter 2025 Earnings: EPS: RM0.029 (vs RM0.021 in 2Q 2024)

KLSE:FIMACOR
Source: Shutterstock

Fima Corporation Berhad (KLSE:FIMACOR) Second Quarter 2025 Results

Key Financial Results

  • Revenue: RM53.4m (up 8.2% from 2Q 2024).
  • Net income: RM6.92m (up 41% from 2Q 2024).
  • Profit margin: 13% (up from 9.9% in 2Q 2024). The increase in margin was driven by higher revenue.
  • EPS: RM0.029 (up from RM0.021 in 2Q 2024).
earnings-and-revenue-history
KLSE:FIMACOR Earnings and Revenue History November 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fima Corporation Berhad shares are down 2.2% from a week ago.

Risk Analysis

Be aware that Fima Corporation Berhad is showing 2 warning signs in our investment analysis and 1 of those makes us a bit uncomfortable...

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:FIMACOR

Fima Corporation Berhad

An investment holding company, engages in the production and trading of travel documents, licences, security, and confidential documents in Malaysia and Indonesia.

Flawless balance sheet with acceptable track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor